The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | PET2-assoicated outcomes in patients with DLBCL
Conflicting data exists on the association between positron emission tomography scans after 2 cycles of therapy (PET2) and survival rates in patients with diffuse large B-cell lymphoma (DLBCL) who progress after rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP). Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, investigates the impact of PET2 on survival in patients with DLBCL. Patients from a Phase II trial (NCT00670358) and the Mayo Clinic Molecular Epidemiology Resource were included in the analysis. Patients who are PET2-postive were found to have inferior overall survival and progression-free survival rates. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
